Literature DB >> 19698075

HIV-1 envelope protein gp120 is present at high concentrations in secondary lymphoid organs of individuals with chronic HIV-1 infection.

Michael Santosuosso1, Elda Righi, Victoria Lindstrom, Pierre R Leblanc, Mark C Poznansky.   

Abstract

The envelope protein of human immunodeficiency virus type 1 (HIV-1)--glycoprotein 120 (gp120)--has been demonstrated to dysregulate T cell function in vitro. We obtained autopsy tissues from individuals with chronic HIV-1 infection to determine whether there was enough gp120 in lymphoid tissues and/or blood to elicit these effects. We found that gp120 was present in high concentrations (>300 pg/mL) in the spleen and lymph nodes of some of these individuals. In contrast, very low amounts of gp120 and p24 were detected in all serum samples tested. These findings underpin the clinical relevance of nonentry functions of gp120 and the chronic nature of human immunodeficiency virus (HIV)-induced immune dysregulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19698075     DOI: 10.1086/605695

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines.

Authors:  Jenna Rychert; Daryld Strick; Sue Bazner; James Robinson; Eric Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08-19       Impact factor: 2.205

2.  HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.

Authors:  Ankita Garg; Stephen A Spector
Journal:  J Infect Dis       Date:  2013-09-01       Impact factor: 5.226

3.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Taylor Mesojednik; Guillermo S Romano Ibarra; Jaya Sahni; Alison Bernard; Karen Sommer; Andrew M Scharenberg; David J Rawlings; Thor A Wagner
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

4.  HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.

Authors:  Rémi Planès; Nawal Ben Haij; Kaoutar Leghmari; Manutea Serrero; Lbachir BenMohamed; Elmostafa Bahraoui
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 5.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

6.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

Review 7.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 8.  Human immunodeficiency virus-associated disruption of mucosal barriers and its role in HIV transmission and pathogenesis of HIV/AIDS disease.

Authors:  Sharof Tugizov
Journal:  Tissue Barriers       Date:  2016-03-03

9.  Histoarchitectural Deterioration of Lymphoid Tissues in HIV-1 Infection and in Aging.

Authors:  Robert L Furler; Kevin L Newcombe; Perla M Del Rio Estrada; Gustavo Reyes-Terán; Christel H Uittenbogaart; Douglas F Nixon
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-07       Impact factor: 2.205

10.  CCR5 as a treatment target in pulmonary arterial hypertension.

Authors:  Larissa Lipskaia; Shariq Abid; Lucie Poupel; Valérie Amsellem; Amal Houssaini; Rozenn Quarck; Elisabeth Marcos; Nathalie Mouraret; Aurélien Parpaleix; Régis Bobe; Guillaume Gary-Bobo; Mirna Saker; Jean-Luc Dubois-Randé; Mark T Gladwin; Karen A Norris; Marion Delcroix; Christophe Combadière; Serge Adnot
Journal:  Circulation       Date:  2014-07-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.